Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
OCTOBER 12, 2018
Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive IPO haul, nearly $300 million. And like Juno, Allogene is working with a live immune-cell treatment called CAR-T, but it is harvesting cells from anonymous donors instead of from the same patients slated to receive the therapy, which is Juno’s method.